About Mark Salangsang

This author has not yet filled in any details.
So far Mark Salangsang has created 12 blog entries.

CIRS RD Briefing 66 – Benefit-Risk Assessment Tool (BRAT)

A structured approach to benefit-risk assessment is required as the cornerstone of a consistent way to evaluate and communicate observations regarding a medicine’s benefit-risk profile. The Benefit Risk Action Team [...]

2020-10-12T10:43:13+00:00January 1st, 2018|Tags: , |
Read More

Liberti et al 2010 – Progress on the development of a benefit-risk framework for evaluating medicines

CIRS authors write about benefit-risk in the March 2010 issue of Regulatory Focus by the Regulatory Affairs Professionals Society (RAPS). Article reproduced with the permission of RAPS. Download [...]

2020-10-12T10:41:12+00:00March 1st, 2010|Tags: , |
Read More
CIRS is a subsidiary of Clarivate plc. View Clarivate's Privacy Policy and Cookie Policy.
© Copyright   Centre for Innovation in Regulatory Science.
EmailLinkedIn